Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oxford BioMedicaOXBDF 72 EV-to-EBITDA is 350.97 as of Jul. 16, 2026. GuruFocus rates OXBDF with a GF Score™ of 72/100 and a GF Value™ of $7.16 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 395 Biotechnology companies, Oxford BioMedica ranks worse than 98.48% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Oxford BioMedica's enterprise value is $1,095.0 Mil.
Oxford BioMedica's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $3.1 Mil. Therefore, Oxford BioMedica's EV-to-EBITDA for today is 350.97.
The historical rank and industry rank for Oxford BioMedica's EV-to-EBITDA or its related term are showing as below:
OXBDF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -75.07 Med: -2.21 Max: 438.4
Current: 327.85
During the past 13 years, the highest EV-to-EBITDA of Oxford BioMedica was 438.40. The lowest was -75.07. And the median was -2.21.
OXBDF's EV-to-EBITDA is ranked worse than 98.48% of 395
companies
in the Biotechnology industry
Industry Median: 13
vs OXBDF: 327.85
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Oxford BioMedica's PE Ratio (TTM) for today is calculated as:
Oxford BioMedica's share price for today is $7.99.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Oxford BioMedica's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.365.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Oxford BioMedica's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OXBDF vs VRTX, REGN, ALNY: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Oxford BioMedica's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oxford BioMedica EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oxford BioMedica's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Oxford BioMedica's EV-to-EBITDA falls into.
Oxford BioMedica's current Enterprise Value is $1,095.0 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Oxford BioMedica's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $3.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oxford BioMedica (OXBDF) has a EV-to-EBITDA of 350.97 as of Jul. 16, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Oxford BioMedica. According to the industry distribution chart, Oxford BioMedica ranks #389 out of 395 companies in the Biotechnology industry, placing it in the top 98.5%.
Is Oxford BioMedica's EV-to-EBITDA too high?
Oxford BioMedica's current EV-to-EBITDA is 350.97. The Biotechnology industry median EV-to-EBITDA is 13.00. Oxford BioMedica's value of 350.97 is 2599.8% above this industry median. Based on the distribution chart, Oxford BioMedica ranks #389 out of 395 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Oxford BioMedica has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oxford BioMedica's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oxford BioMedica ranks #389 out of 395 companies for EV-to-EBITDA. This places Oxford BioMedica in the lower half of its industry. The industry median EV-to-EBITDA is 13.00. Oxford BioMedica's value of 350.97 is 2599.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.00, based on 395 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oxford BioMedica's current EV-to-EBITDA of 350.97 is 2599.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Oxford BioMedica. For the Biotechnology industry, the median EV-to-EBITDA is 13.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oxford BioMedica's current EV-to-EBITDA is 350.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxford BioMedica stock overvalued right now?
Based on GuruFocus' analysis, Oxford BioMedica (OXBDF) is currently considered Modestly Overvalued. The stock's GF Value™ is $7.16, compared to a current price of $7.99 — trading 11.6% above its estimated fair value. The current EV-to-EBITDA is 350.97 and 2599.8% above the Biotechnology industry median of 13.00. Oxford BioMedica's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Oxford BioMedica (OXBDF), the current EV-to-EBITDA is 350.97 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oxford BioMedica (OXBDF) Overvalued in 2026?
Based on GuruFocus' analysis, Oxford BioMedica stock appears to be overvalued.
The current stock price of $7.99 is trading 11.6% above its estimated GF Value™ of $7.16.
GuruFocus considers Oxford BioMedica to be Modestly Overvalued.
Key valuation signals for OXBDF:
EV-to-EBITDA: 350.97
GF Value™: $7.16 vs. price of $7.99 (11.6% above fair value)
Industry Position: 2599.8% above the Biotechnology median (#389 of 395)
No single metric tells the full story. See the OXBDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oxford BioMedica PLC is a contract development and manufacturing organization (CDMO) focused on cell and gene therapy. The company specializes in viral vector development and manufacturing for cell and gene therapy, with expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. Geographically, it derives maximum revenue from the United States, and the rest from Europe, the UK, and the Rest of the world.
72GF Score
Get the complete analysis for OXBDF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OXBDF has been successfully added to your 
